Impel NeuroPharma Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Seattle WA United States (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2017
NCT03401346
First Marketed Drug
2021
dihydroergotamine (D.H.E. 45)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Impel NeuroPharma | IMPEL NEUROPHARMA | Impel NeuroPharma Inc. | Impel NeuroPharma, Seattle, WA (USA)

Active Ingredients

Marketed Drugs (1)

dihydroergotamine (D.H.E. 45) (2021)

Drugs in Phase 3 Trials (1)

dihydroergotamine (D.H.E. 45) (2 trials)

Drugs in Phase 2 Trials (2)

levodopa (larodopa) (1 trial)

olanzapine (zyprexa) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Headache (Phase 3)

Migraine Disorders (Phase 3)

Parkinson Disease (Phase 2)

Psychomotor Agitation (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3